VTGN

VistaGen Therapeutics, Inc.

4.92 USD

Last updated Dec 8, 16:57 UTC

Yesterday HIGH

$5.18

Yesterday LOW

$4.56

52w HIGH

$24.71

52w LOW

$1.62

EPS

-0.66

PE

-7.45

Next Earnings

Feb 6, 2024

Overview News Government Trades

VistaGen Therapeutics, Inc. stock is up 59.74% since 30 days ago. The next earnings date is Feb 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 9 December’s closed higher than November. 100% of analysts rate it a buy.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system. The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

South San Francisco, United States Of America

Website

vistagen.com

Benzinga Newsdesk

Tue Sep 5, 2023

Maxim Group Maintains Buy on Vistagen Therapeutics, Maintains $30 Price Target

Maxim Group analyst Jason McCarthy maintains Vistagen Therapeutics (NASDAQ:VTGN) with a Buy and maintains $30 price target.
Chris Katje

Tue Sep 5, 2023

10 Short Squeeze Stocks To Watch: Blue Apron, Getty Images, Black Rifle Coffee And More

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.
Benzinga Newsdesk

Tue Sep 5, 2023

Vistagen, Fuji Enter Exclusive Negotiation Agreement For Potential License To Develop, Commercialize Vistagen's Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, In Japan; Vistagen To Receive $1.5M

Vistagen to receive $1.5 million and Fuji to obtain time-limited exclusive negotiation period for the Japanese marketRecently reported exploratory Phase 2A study in women diagnosed with menopausal hot flashes
Chris Katje

Mon Aug 28, 2023

10 Short Squeeze Stocks To Watch: Getty Images, Blue Apron, T Stamp, Black Rifle Coffee And More

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.
Happy Mohamed

Tue Aug 22, 2023

Vistagen Appoints Cindy Anderson As Chief Financial Officer; Anderson Succeeds Jerrold Dotson Who Is Retiring After A Distinguished Decade-Long Career With Vistagen, Effective August 21, 2023

Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment
Benzinga Newsdesk

Thu Aug 10, 2023

VistaGen Therapeutics Q1 EPS $(0.94) Up From $(3.00) YoY, Sales $117.00K Down From $310.10K YoY

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.94) per share. This is a 68.67 percent increase over losses of $(3.00) per share from the same period last year. The company reported $117.00 thousand
Lisa Levin

Thu Aug 10, 2023

Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results.
Benzinga Insights

Thu Aug 10, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Happy Mohamed

Thu Aug 10, 2023

AffaMed Therapeutics Announces Partner Vistagen Reports Top-Line Results From Phase 3 PALISADE-2 Trial Of Fasedienol Nasal Spray In Social Anxiety Disorder

First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reduction in patient-reported Subjective Units of Distress Scale (SUDS)
Lisa Levin

Thu Aug 10, 2023

Why AppLovin Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket

Gainers PHAXIAM Therapeutics S.A. (NASDAQ: PHXM) shares surged 46.7% to $0.64 in pre-market trading after gaining 6% on Wednesday.

Jefferies

Thu Dec 7, 05:33

buy

upgrade
Stifel

Tue Nov 14, 12:46

buy

initial